Vor Biopharma: Pivot to Autoimmune Gains Traction but Dilution and Competition Loom

What happened

Vor Biopharma has completed a dramatic transformation from a failed oncology platform to a late-stage autoimmune drug developer centered on telitacicept, a dual BAFF/APRIL inhibitor with strong China Phase 3 data in gMG, Sjögren’s, and IgAN. The company holds $491.5 million in cash, extending runway into early 2029 and enabling pivotal readouts before needing additional capital. However, despite the compelling clinical narrative, the DeepValue report flags a compressed patent tail (ex-China composition of matter expiring ~2028), heavy dilution from a warrant-laden capital structure, and a crowded gMG market where larger competitors are already entrenched. The stock has rallied sharply since the pivot, but the fundamental risk/reward remains skewed: the market may be underestimating both the execution hurdles and the structural dilution from the $80 million low-strike warrant issued to RemeGen.

Implication

If global Phase 3 gMG results replicate China's efficacy and safety, telitacicept could become a meaningful autoimmune asset. However, investors must account for heavy milestone/royalty obligations and a narrow patent window; success is partially priced in at current levels.

Thesis delta

The new article emphasizes the substance of Vor's autoimmune pivot and strong financing, slightly increasing conviction in telitacicept's potential versus the DeepValue report's more cautious stance. However, the core risks—dilution, patent cliff, and competitive pressure—remain unchanged. The thesis shifts from 'wait and see' to 'watch closely for enrollment milestones,' but the recommended entry point remains at lower prices.